For us as advocates, the message is clear: celebrate the progress, but guard against the hype. Stories of individual breakthroughs are moving — but without long-term, carefully designed trials that measure not just detection but survival, we risk creating false reassurance or unnecessary harm.
The real “holy grail” is not simply detecting cancer earlier. It is learning to distinguish between cancers that demand urgent treatment and those that do not; between signals of danger and signals of noise. Only then will early detection truly translate into lives saved.
Lynch Syndrome Ireland 